Infertility Hormone Compounding Pharmacy: The Clinical Guide for Fertility Patients and REIs in 2026
Introduction: Why Compounded Fertility Hormones Matter More Than Ever in 2026
Infertility is no longer a rare or private struggle. According to the World Health Organization, roughly 1 in 6 people of reproductive age (about 17.5% of the adult population) experience infertility at some point in their lives. That reality is driving unprecedented demand for individualized treatment, and the numbers reflect it. The global IVF market was valued at approximately $28 to $32 billion in 2025 and is projected to reach $51 to $69 billion by 2034, growing at a compound annual growth rate of 6.9% to 8.8%. In the United States specifically, analysts expect an 11.0% CAGR between 2026 and 2036, fueled largely by employer benefit packages that now include fertility coverage.
Yet a critical clinical problem persists beneath these figures. Commercial fertility medications come in fixed doses and a narrow set of delivery forms. A patient who needs 73 units of a hormone cannot always get there when the vial comes in 50 or 100 unit increments. Compounding pharmacies fill exactly this gap.
This guide serves two audiences: fertility patients researching whether compounded hormones fit their protocol, and reproductive endocrinologists (REIs) evaluating a compounding pharmacy partner. It covers which hormones are compounded and why, what the peer-reviewed evidence shows for key adjuvants, how the regulatory landscape shifted between 2020 and 2026, and what to look for in a pharmacy partner. It also examines the February 2026 launch of TrumpRx.gov, an IVF drug discount program that, as this article will show, highlights rather than resolves the gap that compounding pharmacies fill.
What Is an Infertility Hormone Compounding Pharmacy?
Pharmaceutical compounding in the fertility context means preparing customized hormone medications tailored to an individual patient when commercially available products are inadequate. The FDA defines compounding as combining, altering, or mixing drug ingredients to create a patient-tailored medication. Importantly, compounded drugs are not FDA-approved as finished products and do not undergo the same pre-market safety and efficacy review as commercial drugs. This is a critical transparency point that every patient and prescriber must understand.
A general compounding pharmacy differs meaningfully from a specialty infertility hormone compounding pharmacy. The latter requires sterile compounding capabilities under USP Chapter 797, hazardous drug handling under USP Chapter 800, and deep familiarity with assisted reproductive technology (ART) protocol requirements. To understand what pharmaceutical compounding is and how it works at a foundational level, patients new to this space should start there.
Two regulatory tiers matter here. 503A pharmacies prepare patient-specific prescriptions, are state-regulated, and offer maximum flexibility for individualized protocols. 503B outsourcing facilities are FDA-registered, compound in bulk for healthcare providers, and operate under stricter federal oversight and cGMP standards.
Above the regulatory minimum sits accreditation. PCAB accreditation, administered by ACHC, is held by only about 1% of U.S. compounding pharmacies, making it a decisive differentiator. Nationwide Compounding Rx® sits within this landscape as a PCAB-accredited, USP 800-compliant 503A pharmacy serving 47 states plus Washington, D.C., with 40 years of combined staff experience.
The Six Core Hormones Compounded for Fertility
This section provides the clinical foundation for understanding fertility compounding. It is not simply a list of what is compounded but an explanation of why compounding is necessary at each stage of an ART or IVF cycle. The unifying theme is the dosing mismatch problem: patients often need doses and delivery forms that no commercial product provides.
Progesterone: The Cornerstone of Luteal Phase Support
Progesterone supports the endometrium for embryo implantation and maintains early pregnancy. In ART cycles where the natural luteal phase is suppressed, this support is essential. Commercial options are limited: Prometrium oral capsules contain peanut oil, and Crinone vaginal gel is a fixed 8% dose. Compounding allows vaginal suppositories, intramuscular injections, topical creams, sublingual tablets, and custom-strength vaginal gels.
Delivery method carries clinical consequences. Vaginal progesterone achieves higher local uterine concentrations through the first-uterine-pass effect and is often preferred in frozen embryo transfer (FET) cycles. Intramuscular progesterone in oil provides sustained systemic levels. Topical creams offer a needle-free option for patients with injection anxiety. For patients allergic to peanut oil, compounded progesterone is a direct patient safety necessity. Dosing can also be adjusted each cycle based on serum progesterone monitoring.
Estradiol: Precision Endometrial Preparation
Estradiol builds and maintains the endometrial lining in FET cycles, typically to a target thickness of 7 to 8 mm or greater before progesterone supplementation begins. Commercial estradiol patches come in fixed doses (0.025 to 0.1 mg/day). Compounding permits precise titration, combination formulations, and alternative routes such as transdermal creams, vaginal suppositories, and sublingual tablets for patients who cannot tolerate oral or patch delivery. Patients who react to patch adhesives or tablet excipients benefit from compounded transdermal creams. Notably, estradiol is one of the 11 cBHT hormones currently under FDA review for potential placement on the Difficult to Compound List, a development worth monitoring closely.
DHEA: The Evidence-Backed Ovarian Reserve Adjuvant
DHEA is a precursor androgen that upregulates FSH receptor expression in granulosa cells, potentially improving follicular response in women with diminished ovarian reserve (DOR) or poor ovarian response (POR). The evidence is substantial. A retrospective cohort of 151 poor ovarian responders found DHEA supplementation positively associated with clinical pregnancy rate (OR = 4.93, 95% CI 1.68 to 14.43, p = 0.004). A randomized prospective study reported a live birth rate of 23.1% versus 4.0% in controls (p = 0.05). A Frontiers in Endocrinology retrospective cohort of 297 IVF cycles showed improved oocyte yield, embryo quality, and cumulative pregnancy rates in POSEIDON Group 4 patients.
The standard compounded protocol is typically 75 to 90 mg/day (often 25 to 30 mg three times daily) for 12 weeks before IVF stimulation, a dose and duration not available in any single commercial product. Because commercial DHEA is sold over the counter as a dietary supplement without pharmaceutical-grade quality controls, compounding from an FDA-inspected API source provides verified potency and purity. Understanding the difference between OTC and prescription compounded DHEA is essential for patients and prescribers evaluating this adjuvant. A systematic review concluded that pre-treatment with DHEA may correlate with enhanced live birth rates, supported by moderate-quality evidence. DHEA is also among the 11 hormones under FDA cBHT review.
Testosterone: Transdermal Priming for Poor Ovarian Responders
Androgens enhance FSH receptor expression and intraovarian IGF-1 activity, potentially sensitizing the ovary to gonadotropin stimulation in POR patients. No commercial transdermal testosterone product is FDA-approved for women, so compounding is the only route to appropriate female dosing (typically 5 to 10 mg/day transdermal, far below male products). The goal is ovarian priming, not systemic androgen replacement. Delivery is usually a transdermal cream or gel applied to the inner thigh or abdomen for 4 to 6 weeks before stimulation. Testosterone is likewise one of the 11 hormones under FDA cBHT review.
Leuprolide Acetate: Custom GnRH Agonist Protocols
Leuprolide is a GnRH agonist used in long lupron and micro-dose lupron flare protocols to suppress premature LH surges and control follicular timing. Commercial Lupron comes in fixed depot formulations, but compounding allows micro-dose preparations (for example, 40 mcg twice daily) used specifically in poor ovarian responders. Because leuprolide is a small-molecule drug rather than a biologic, it was not affected by the 2020 FDA biologics reclassification. Compounded leuprolide can also be significantly less expensive than commercial Lupron.
hCG: Access Crisis and the 2020 FDA Mandate
Human chorionic gonadotropin serves a dual role: as a trigger shot inducing final oocyte maturation before egg retrieval, and as a cornerstone of male fertility treatment by stimulating testosterone and sperm production. In 2020, the FDA reclassified hCG, FSH, and HMG as biologics requiring a Biologics License Application, effectively banning their compounding by 503B facilities. A Journal of Sexual Medicine survey found that of 76 FDA-registered 503B pharmacies, only 5 (6.58%) still provided compounded hCG afterward, and 6 of 8 former providers cited the mandate as the reason for stopping.
The male infertility impact is severe. Men with hypogonadism-related infertility who cannot use testosterone replacement (which suppresses sperm production) rely on compounded hCG plus FSH. Compounded hCG was available at $50 to $83 per vial and compounded FSH at roughly $287 per month, far below brand alternatives. 503A pharmacies may still compound hCG for patient-specific prescriptions in some states, though this remains a complex and evolving area. TrumpRx.gov does not address compounded hCG or the male infertility access gap.
The Regulatory Landscape Reshaping Fertility Compounding in 2026
The regulatory environment is actively changing, which makes working with an accredited, compliance-focused pharmacy more important than ever.
The 2020 FDA Biologics Reclassification: What It Means Today
The Drug Quality and Security Act of 2013 created the 503A/503B framework. The 2020 reclassification extended FDA authority to classify protein-based hormones as biologics requiring BLAs. As a study on gonadotropin availability documented, 503B facilities can no longer compound hCG or FSH, forcing clinics toward expensive brand alternatives or the limited 503A pathway. The Endocrine Society notes that 30% to 40% of male infertility cases have no identifiable cause beyond hormonal dysregulation, so the affected population is significant. Leuprolide, progesterone, estradiol, DHEA, and testosterone are small molecules unaffected by this change.
The cBHT Difficult to Compound List: A Threat to Access
Under the DQSA, the FDA can designate drugs as too difficult or risky to compound, banning them across both 503A and 503B pharmacies. As legal analysis has detailed, 11 cBHT hormones are under review, including estradiol, estriol, progesterone, testosterone, and DHEA, all of which are used in fertility protocols. Over 2.5 million U.S. women rely on bioidentical hormones. As of mid-2026, the review is ongoing with no final determinations, but it represents a material risk that REIs and patients should monitor.
503A vs. 503B: Which Framework Matters?
503A pharmacies prepare patient-specific prescriptions only, operate under state pharmacy board oversight, can compound from bulk APIs, and offer maximum formulation flexibility. 503B facilities are FDA-registered, compound in bulk without patient-specific prescriptions, undergo FDA inspections and cGMP standards, but cannot compound biologics like hCG and FSH. For highly individualized protocols (custom DHEA doses, allergen-free progesterone, micro-dose leuprolide), 503A offers the most flexibility. PCAB accreditation applies to both and adds an independent quality layer. Nationwide Compounding Rx® is a PCAB-accredited 503A pharmacy, combining protocol flexibility with verified quality.
TrumpRx.gov and the IVF Drug Discount Gap
Launched in February 2026, TrumpRx.gov offers up to 84% discounts on three brand-name IVF medications (Gonal-F, Ovidrel, and Cetrotide) from EMD Serono, with CVS Health as a distribution partner. The American Society for Reproductive Medicine responded that IVF access requires more than lower drug prices. TrumpRx does not cover compounded formulations, Follistim, Menopur, Bravelle, custom protocols, DHEA, transdermal testosterone, compounded progesterone, leuprolide, or any male infertility medication. Even with discounts, a full IVF cycle still costs $11,000 to $25,000. The program’s limitations underscore the clinical necessity of compounding.
Compounded Fertility Hormones for Poor Ovarian Responders and Diminished Ovarian Reserve
Women with DOR or POR under the POSEIDON criteria are the group most likely to benefit from compounded adjuvants. Standard protocols with fixed doses cannot accommodate the individualized, multi-agent regimens these patients require. The evidence-based toolkit includes DHEA (75 to 90 mg/day for 12 weeks), transdermal testosterone priming (5 to 10 mg/day for 4 to 6 weeks), micro-dose leuprolide flare protocols, and custom gonadotropin formulations.
Mechanistically, DHEA and testosterone upregulate FSH receptors on granulosa cells, increase intraovarian androgen concentrations, and may improve oocyte mitochondrial function, all of which are impaired in DOR. For this population, the required doses and delivery forms are simply not available commercially. Compounding is not a preference but a clinical necessity. The 2025 to 2026 shift toward genetic profiling and AI-assisted embryo selection is further increasing demand for customized medications aligned to individualized stimulation plans.
Male Infertility and Compounding: The Fastest-Growing and Most Underserved Segment
Male infertility is the fastest-growing IVF segment yet remains significantly underserved. Hypogonadism impairs spermatogenesis, and as noted, 30% to 40% of cases have no identifiable cause beyond hormonal dysregulation. The compounded toolkit includes hCG (stimulating Leydig cell testosterone and spermatogenesis), FSH (stimulating Sertoli cells), clomiphene citrate (a SERM raising endogenous LH/FSH), anastrozole (an aromatase inhibitor reducing estrogen conversion), and specific testosterone formulations. Patients and clinicians can learn more about the full scope of compounding pharmacy for men’s health and how these formulations are prepared.
A critical distinction applies here: exogenous testosterone suppresses the HPG axis and halts sperm production. Men who want to preserve fertility while treating hypogonadism must use hCG plus FSH plus SERMs instead. The post-2020 access crisis (only 5 of 76 503B pharmacies providing hCG) hit this population hardest, and TrumpRx covers zero male infertility medications. Patient-specific compounded hCG may remain available through 503A pharmacies in many states, so REIs should confirm current availability with their pharmacy partner.
Why Delivery Form Matters: Matching Formulations to Clinical Needs
Delivery form is not merely patient preference. It affects bioavailability, local versus systemic concentrations, adherence, and cycle outcomes. Compounding pharmacies can prepare fertility hormones as vaginal suppositories, transdermal creams and gels, sublingual troches, injection solutions, custom oral capsules, and combination formulations.
Vaginal Progesterone: The First-Uterine-Pass Advantage
Vaginal progesterone achieves high local uterine concentrations with lower systemic levels than intramuscular injection, which is clinically relevant for FET endometrial support. Many patients prefer suppositories over daily injections, especially across 8 to 10 week FET protocols. Unlike fixed 8% Crinone, compounding allows custom strengths (100 mg, 200 mg, 400 mg) and allergen-free bases. Because Prometrium contains peanut oil, compounded alternatives are a safety necessity for peanut-allergic patients. For patients with sensitivities to common excipients, compounding for allergy to medication ingredients is a core capability that directly addresses this clinical need.
Transdermal Creams and Gels: Precision Dosing
Transdermal delivery avoids first-pass hepatic metabolism, enables precise low dosing, and provides steady-state hormone levels. For women needing 5 to 10 mg/day testosterone for ovarian priming, no commercial product exists; compounded cream is the only pharmaceutical-grade option. Custom estradiol creams allow precise titration for FET, particularly for patients who react to patch adhesives. Given that a missed dose can jeopardize a $11,000 to $25,000 cycle, better-tolerated topicals directly support adherence.
Sublingual and Oral Formulations: When Systemic Delivery Is Preferred
Sublingual solution compounding allows troches to dissolve under the tongue for rapid absorption while bypassing first-pass metabolism, making them useful for progesterone, DHEA, and estradiol. Patients unable to use vaginal suppositories may prefer sublingual progesterone. Custom oral capsules allow precise doses without lactose, gluten, or dyes, which is particularly valuable for DHEA. Combination formulations can also unite multiple hormones in one capsule or troche, simplifying complex protocols and improving adherence.
How to Evaluate an Infertility Hormone Compounding Pharmacy
Not all compounding pharmacies are equal. Quality, safety, and compliance directly affect patient outcomes and clinic liability.
Accreditation: The Non-Negotiable Quality Signal
PCAB accreditation assesses pharmacies against USP Chapters 795 (non-sterile), 797 (sterile), and 800 (hazardous drugs). Only about 1% of U.S. compounding pharmacies hold it, making it a powerful trust signal. For fertility patients, it means independent third-party verification of sterility, potency, purity, and quality control, not self-reported compliance. URAC and ACHC provide additional verification; state licensing is the minimum. Nationwide Compounding Rx® has maintained PCAB accreditation since its early days. Patients and REIs should verify accreditation directly with the accrediting body.
Sterile Compounding Capabilities
Injectable medications (progesterone in oil, leuprolide, hCG) must be prepared in ISO-classified cleanrooms under USP 797 to prevent microbial contamination. USP 800 compliance protects staff and patients from cross-contamination of hazardous drugs. Non-sterile pharmacies cannot legally prepare injectables, so REIs should confirm sterile capabilities before partnering. Sterile preparations should undergo third-party testing for potency, sterility, and endotoxins. Nationwide Compounding Rx® operates a USP 800-compliant facility and sources chemicals exclusively from high-quality, FDA-inspected and cleared vendors.
Turnaround Time, Shipping, and Clinical Support
IVF protocols are time-sensitive; a delivery delay can force cancellation of a $11,000 to $25,000 cycle. Nationwide Compounding Rx® offers 1 to 2 business day turnaround on all medications and same-day pickup for some formulations, with shipping to 47 states plus Washington, D.C. (not currently serving Alabama, California, North Carolina, or South Carolina). Extended pharmacist access matters because patients frequently face urgent questions on administration and storage. The best pharmacy partners work collaboratively on custom protocol development and allergen-free formulation, removing lactose, peanut oil, gluten, and dyes as needed.
Compounded vs. Commercial Fertility Hormones: A Clinical and Cost Comparison
Compounding does not replace commercial medications where those adequately meet clinical needs. It is a clinically necessary alternative when they do not.
When Commercial Products Are Sufficient, and When They Are Not
Commercial products are appropriate for standard stimulation in normal responders using standard-dose gonadotropins, and for triggers in patients without allergen sensitivities. Compounding becomes necessary for doses outside commercial ranges, allergies to excipients (peanut oil in Prometrium, patch adhesives), non-commercial delivery forms (transdermal testosterone for women, micro-dose leuprolide, custom vaginal progesterone), POR priming with DHEA or testosterone, and male infertility hCG plus FSH protocols. As a Cedars-Sinai article featuring a reproductive endocrinologist clarified, compounding is appropriate when commercial alternatives are inadequate, provided the pharmacy holds PCAB accreditation and performs third-party testing. The FDA non-approval status must be disclosed transparently, even as the evidence for specific adjuvants like DHEA remains substantial.
Cost Considerations
Compounded hCG was available at $50 to $83 per vial and FSH at roughly $287 per month before 2020 restrictions, well below brand costs. Even with TrumpRx discounts, a full cycle still costs $11,000 to $25,000, and many needed medications remain uncovered. The adherence economics are decisive: allergen-free options, preferred delivery routes, and simplified combinations prevent cancellations that each cost a full cycle. Most compounded medications are not covered by insurance, though the corporate benefit trend driving the 11.0% U.S. CAGR may create new coverage pathways. Pricing requires a prescription and consultation; Nationwide Compounding Rx® does not publish pricing publicly.
Personalized Medicine and the Future of Fertility Compounding
The 2025 to 2026 convergence of genetic profiling, pharmacogenomics, and AI-assisted embryo selection is generating demand for increasingly individualized stimulation protocols that fixed commercial products cannot serve. When a genetic profile reveals an FSH receptor polymorphism requiring a non-standard dose, or pharmacogenomic data suggests a specific progesterone metabolizer phenotype, compounding is the only mechanism to implement that precision. As these technologies become standard of care, medication protocols will grow more individualized, increasing rather than decreasing the necessity of compounding. This is the core promise of personalized medicine pharmacy, where formulations are built around the individual patient rather than population averages.
Male infertility, the fastest-growing segment, will drive further demand for compounded testosterone, hCG where available, FSH, SERMs, and aromatase inhibitors, making the post-2020 access crisis an urgent clinical and policy issue. With the broader fertility market projected to reach $92.60 billion by 2035 at an 8.96% CAGR, the compounding sector is positioned for significant growth, provided regulatory access to key hormones is preserved. In this environment, the REI-pharmacy relationship becomes a clinical partnership, not a transactional one. REIs evaluating how to structure that relationship can find practical guidance on how to partner with a compounding pharmacy as a prescriber.
Conclusion: Compounded Fertility Hormones as a Clinical Necessity, Not a Niche Option
For a large and growing subset of patients (poor ovarian responders, those with allergen sensitivities, male infertility patients, and anyone requiring precision dosing) compounded fertility hormones are not an alternative to commercial products but a clinical necessity. The evidence base is real: peer-reviewed studies support compounded DHEA (OR = 4.93 for clinical pregnancy, live birth 23.1% vs. 4.0%) and transdermal testosterone as adjuvants for POR patients, while compounded progesterone, estradiol, and leuprolide fill critical ART gaps.
The regulatory picture is complex. The 2020 biologics reclassification, the ongoing cBHT Difficult to Compound List review, and TrumpRx’s limitations all underscore the value of a pharmacy that actively monitors and adapts. With only about 1% of U.S. compounding pharmacies PCAB-accredited, accreditation remains the single most important quality signal. As fertility medicine moves toward greater personalization, the infertility hormone compounding pharmacy will only become more central to optimal outcomes. Nationwide Compounding Rx® stands as a PCAB-accredited, USP 800-compliant 503A pharmacy with 40 years of combined experience, nationwide shipping to 47 states, and 1 to 2 business day turnaround, built for precision fertility medicine.
Partner With Nationwide Compounding Rx® for Your Fertility Protocol
Whether a fertility patient needs customized hormone formulations for an IVF or ART cycle, or a reproductive endocrinologist is seeking a trusted, accredited pharmacy partner, Nationwide Compounding Rx® is built to serve complex fertility needs. Key advantages include PCAB accreditation (top approximately 1% of U.S. compounding pharmacies), a USP 800-compliant sterile facility, 1 to 2 business day turnaround, nationwide shipping to 47 states plus Washington, D.C., allergen-free formulation capability, and collaborative pharmacist support for complex protocols.
Contact: Phone 480-499-8379 or toll-free 1-833-650-9836. Fax 480-699-5341. Website: www.NationwideCompounding.com. Location: 14000 N. Hayden Rd., Suite 104, Scottsdale, AZ 85260. Hours: Monday through Friday, 7:00 a.m. to 3:30 p.m.
For REIs: Contact Nationwide Compounding Rx® to discuss a pharmacy partnership, including custom protocol support, sterile compounding capabilities, and clinical consultation.
For patients: Ask your reproductive endocrinologist whether compounded formulations are appropriate for your protocol, and request that prescriptions be sent to Nationwide Compounding Rx®.
All compounded fertility medications require a valid prescription from a licensed provider. Compounded medications are not FDA-approved as finished products; patients should discuss the clinical rationale, evidence base, and regulatory status of any compounded medication with their reproductive endocrinologist.
